Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

1
Player Avatar hawkider (51.45) Submitted: 12/7/2006 4:04:53 PM : Underperform Start Price: $9.52 DVAX Score: +134.64

House of cards

Featured Broker Partners


Advertisement